Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Carsten, Hielscher"'
Autor:
Philipp Ziegler, Andreas D. Hartkopf, Markus Wallwiener, Lothar Häberle, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller, Laura L. Michel, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Hanna Huebner, Sabrina Uhrig, Lena A. Wurmthaler, Carolin C. Hack, Christoph Mundhenke, Christian Kurbacher, Peter A. Fasching, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss, Chloë Goossens
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Although adequate physical activity has been shown to be beneficial in early breast cancer, evidence in metastatic breast cancer is sparse and contradictory, which could be related to distinct effects of physical activity on the d
Externí odkaz:
https://doaj.org/article/f6addaf5728b4463afe3407a59ff7008
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 54, Iss , Pp 88-95 (2020)
Purpose: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of th
Externí odkaz:
https://doaj.org/article/06b4953fd7094428a800955c7f592096
Autor:
Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss
Publikováno v:
Senologie - Zeitschrift für Mammadiagnostik und -therapie. 20:43-56
Zusammenfassung Hintergrund Umfangreiche Daten aus prospektiven klinischen Studien liefern einen hohen Evidenzgrad für den Einsatz von CDK4/6-Hemmern in Kombination mit einer endokrinen Therapie (CDK4/6i + ET) als Standard bei der First-Line-Behandl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e74ba3c06bc446cf560ab25f46195a
https://doi.org/10.1055/a-2008-6553
https://doi.org/10.1055/a-2008-6553
Autor:
Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Nicolas Schleif, Ursula Cirrincione, Axel Hinke, Gabriele Feisel-Schwickardi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence from clinical studies. Methods
Externí odkaz:
https://doaj.org/article/e43f4c5e114d4a3d89db10e70b8f4cd8
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 55, Iss , Pp 138-139 (2021)
Externí odkaz:
https://doaj.org/article/3ce18d162da74f4b92ea7082883a3131
Autor:
Tobias, Engler, Peter A, Fasching, Diana, Lüftner, Andreas D, Hartkopf, Volkmar, Müller, Hans-Christian, Kolberg, Peyman, Hadji, Hans, Tesch, Lothar, Häberle, Johannes, Ettl, Markus, Wallwiener, Matthias W, Beckmann, Alexander, Hein, Erik, Belleville, Sabrina, Uhrig, Pauline, Wimberger, Carsten, Hielscher, Christian M, Kurbacher, Rachel, Wuerstlein, Michael, Untch, Florin-Andrei, Taran, Hans-Martin, Enzinger, Petra, Krabisch, Manfred, Welslau, Michael, Maasberg, Dirk, Hempel, Michael P, Lux, Laura L, Michel, Wolfgang, Janni, Diethelm, Wallwiener, Sara Y, Brucker, Tanja N, Fehm, Andreas, Schneeweiss
Publikováno v:
Geburtshilfe und Frauenheilkunde. 82:1055-1067
Background Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b025963af12454faef60ebf08259e4
https://doi.org/10.1055/a-1880-0087
https://doi.org/10.1055/a-1880-0087
Autor:
Matthias W. Beckmann, Lothar Häberle, Christoph Thomssen, Michael P. Lux, Rachel Wuerstlein, Michael Untch, Friedrich Overkamp, Peyman Hadji, Tanja Fehm, Bernhard Volz, Erik Belleville, Alexander Hein, Wolfgang Janni, Hans Tesch, Andreas Schneeweiss, Lena A. Wurmthaler, Christian M. Kurbacher, Johannes Ettl, Carsten Hielscher, Florin-Andrei Taran, Volkmar Müller, Andreas D. Hartkopf, P Wimberger, Sara Y. Brucker, Hans-Christian Kolberg, Diana Lüftner, Diethelm Wallwiener, Peter A. Fasching, Julius Emons, Markus Wallwiener
Publikováno v:
European Journal of Cancer. 155:1-12
Purpose Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff9454fc61f6be3b80d26db44b681593
https://doi.org/10.1016/j.ejca.2021.06.033
https://doi.org/10.1016/j.ejca.2021.06.033
Autor:
Christiane D Matillon, Michael Metz, Ulrich Hutzschenreuter, Mark-Oliver Zahn, Steffen Liebers, Andreas Lorenz, Dieter Semsek, Gerlinde Egerer, Michael Berghorn, Carsten Hielscher, Stefan Zacharias, Johanna Harde, Gunther Rogmans, Sina Grebhardt, Karin Potthoff, Dagmar Guth, Thomas Fietz
Publikováno v:
Supportive Care in Cancer
Purpose The on-body injector (OBI) automatically delivers pegfilgrastim the day after chemotherapy (CTx), thus eliminating the need of return visits to the medical office for guideline-compliant pegfilgrastim administration. The CONVENIENCE study aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::514d4e3f09dea24ed5dc11624667452c
https://doi.org/10.1007/s00520-021-06230-9
https://doi.org/10.1007/s00520-021-06230-9
Autor:
Jörg Schilling, Pia Wülfing, Elisa Flahaut, Carsten Hielscher, Mark-Oliver Zahn, Dagmar Guth, Meinolf Karthaus, Gülten Oskay-Özcelik
Publikováno v:
Future Oncology. 16:939-953
Aim: To determine quality of life, effectiveness and safety of oral netupitant-palonosetron (NEPA)–based antiemetic prophylaxis in the real-world setting. Materials & methods: Prospective, noninterventional study in adults receiving highly or moder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc7877c861a8941227b3e2891b5c1e9a
https://doi.org/10.2217/fon-2020-0187
https://doi.org/10.2217/fon-2020-0187
Autor:
Volkmar Müller, Alexander Hein, Andreas D. Hartkopf, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Matthias W. Beckmann, Andreas Schneeweiss, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Julia Meyer, Lena A. Wurmthaler, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Laura L. Michel
Publikováno v:
European journal of cancer (Oxford, England : 1990). 172
Patients with de novo metastatic breast cancer (dnMBC) may have different clinical and pathological characteristics. In studies concerned with first-line metastatic patients, the proportion of these patients without secondary resistance mechanisms ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5381376a41171712ae85184a0ca56007
https://pubmed.ncbi.nlm.nih.gov/35728342
https://pubmed.ncbi.nlm.nih.gov/35728342